Alnylam Pharma (ALNY) Announces Completion of ENDEAVOUR Phase 3 Enrollment
Tweet Send to a Friend
Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), announced that it has completed enrollment in its ENDEAVOUR Phase 3 study with revusiran, an ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
